Remote Ischemic Conditioning in Patients Undergoing Primary Percutaneous Coronary Intervention
NCT ID: NCT07272408
Last Updated: 2025-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
2 participants
INTERVENTIONAL
2022-09-01
2023-12-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Ischemic Post-conditioning
NCT04068116
Cardio- and Renoprotective Effect of Remote Ischemic Preconditioning in Patients Undergoing Percutaneous Coronary Intervention
NCT02313441
Positive Effect of Ischemic Postconditioning During Acute Myocardial Infarction
NCT00333320
Remote Myocardial Ischemic Preconditioning in Humans
NCT00588042
Remote Postconditioning in Patients With Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention (PCI)
NCT00865722
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary percutaneous coronary intervention (PPCI) is a reperfusion therapy that is carried out in patients who usually have ST-segment elevation MI (STEMI) within a specific time window.
During ischemia, metabolic acidosis occurs due to anaerobic metabolism, and ischemic injury ensues. After restoration of blood supply, reactive oxygen species (ROS) production and local inflammation increase secondary injury.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Remote ischemic conditioning
Remote ischemic conditioning (RIC) was applied to those patients.
Remote ischemic conditioning
Remote ischemic conditioning (RIC) was applied to those patients.
Normal primary percutaneous coronary intervention
Patients followed the standard primary percutaneous coronary intervention pathway.
Normal primary percutaneous coronary intervention
Patients followed the standard primary percutaneous coronary intervention pathway.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Remote ischemic conditioning
Remote ischemic conditioning (RIC) was applied to those patients.
Normal primary percutaneous coronary intervention
Patients followed the standard primary percutaneous coronary intervention pathway.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Both sexes.
* Patients with new ST-segment elevation at the J-point in V1:V6 leads with the cut-point: ≥ 1mm other than leads V2-V3 where the following cut-points apply: ≥ 2mm in men ≥ 40 years; ≥ 2.5mm in men \< 40 years, or ≥ 1.5mm in women regardless of age.
* Patients with new left bundle branch block (LBBB).
Exclusion Criteria
* Severe comorbidities (uncontrolled hypertension, morbid obesity, recent cerebrovascular stroke, respiratory failure, sepsis, and stage 4 \& 5 malignancy).
* End-stage renal disease on hemodialysis.
* Previous coronary artery bypass graft surgery (CABG).
* Myocardial infarct within the previous 30 days.
* Multi-vessel coronary artery disease.
* Failure of culprit vessel recanalization.
* Conditions precluding use of remote conditioning ie: paresis of upper limb.
* Life expectancy of less than 1 year due to a non-cardiac pathology.
* Patients who receive nephrotoxic drugs such as non-steroidal anti-inflammatory drugs and aminoglycosides.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Helwan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ahmed Yousry Mousa
Resident of Cardiology, Helwan University, Helwan, Egypt
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Helwan University
Helwan, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
40-2022
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.